Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.490 -0.050 (-3.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Gapping stocks in Monday's session ↗
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial ↗
The primary endpoint of the study was not met in the intent-to-treat population, the company said. 
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from INmune Bio's Earnings ↗
 
Via Benzinga
News headline image
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Why Venus Concept Shares Are Trading Higher By Over 32%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes ↗
INmune Bio stock rose sharply on high volume ahead of topline Phase 2 trial data for XPro in early Alzheimer's, expected on June 30. 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week ↗
INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
News headline image
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.